Firebrick Pharma Expands Nasodine Range and International Footprint as Sales and Cost Discipline Improve

Firebrick Pharma Limited ( (AU:FRE) ) has issued an announcement.

Firebrick Pharma reported solid operational progress in the December 2025 quarter, highlighted by the first expansion of its Nasodine product range with the Nasodine Throat Spray moving into commercial manufacturing, securing Australian approval for export and launching into Singapore with initial promotion to government hospitals and online consumer sales. The company outlined a clear international growth strategy, including expanded promotion in the US, broader pharmacy distribution in Singapore, the first orders for Fiji, a regulatory review underway in the Philippines and active exploration of additional Southeast Asian and Middle Eastern markets, while user survey data showed very high satisfaction with Nasodine Nasal Spray and financial discipline delivered lower operating costs and 15% year-on-year growth in quarterly cash sales, positioning Firebrick for reduced cash burn as revenues scale.

The most recent analyst rating on (AU:FRE) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Firebrick Pharma Limited stock, see the AU:FRE Stock Forecast page.

More about Firebrick Pharma Limited

Firebrick Pharma Limited is an Australian pharmaceutical company focused on developing and commercialising povidone-iodine based Nasodine-branded products for respiratory health, including its flagship Nasodine Nasal Spray. The company is targeting international markets such as Singapore, the United States, Fiji, the Philippines and broader Southeast Asia and the Middle East through licensing partners, hospital channels, retail pharmacies and online sales.

Average Trading Volume: 102,372

Technical Sentiment Signal: Hold

Current Market Cap: A$16.1M

For detailed information about FRE stock, go to TipRanks’ Stock Analysis page.